C-DB8NScripta Therapeutics
transcription factors, AI/ML, patient-derived models
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-DB8N
C-DB8NC-DB8Ntranscription factors, AI/ML, patient-derived models
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Scripta Therapeutics transcription factors, AI/ML, patient-derived models
Scripta Therapeutics is focused on modulating transcription factor activity to restore health. The company uses genome-wide mapping of transcription factors, AI/ML models, molecule and target prediction, and validation in patient-derived models. Its first focus is neurodegenerative diseases including Alzheimer’s, Parkinson’s and ALS.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Scripta Therapeutics — Early mechanism · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic